Trials / Active Not Recruiting
Active Not RecruitingNCT04898634
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 216 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-78278343 | JNJ-78278343 will be administered. |
Timeline
- Start date
- 2021-07-13
- Primary completion
- 2027-02-10
- Completion
- 2027-02-10
- First posted
- 2021-05-24
- Last updated
- 2026-04-13
Locations
17 sites across 6 countries: United States, China, France, Japan, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04898634. Inclusion in this directory is not an endorsement.